Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, womenâs health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
äŒæ¥ã³ãŒãEVO
äŒç€ŸåEvotec SE
äžå Žæ¥Oct 11, 1999
æé«çµå¶è²¬ä»»è
ãCEOãWojczewski (Christian)
åŸæ¥å¡æ°4827
蚌åžçš®é¡Depository Receipt
æ±ºç®ææ«Oct 11
æ¬ç€Ÿæåšå°Essener Bogen 7
éœåžHAMBURG
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœGermany
éµäŸ¿çªå·22419
é»è©±çªå·4940560810
ãŠã§ããµã€ãhttps://www.evotec.com/
äŒæ¥ã³ãŒãEVO
äžå Žæ¥Oct 11, 1999
æé«çµå¶è²¬ä»»è
ãCEOãWojczewski (Christian)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã